He is in charge of high throughput drug screening projects using human iPS-derived retinal cells for the treatment of inherited and complex retinal degenerative diseases and his expertise and scientific interests are:
- Drug and target discovery
- High-throughput screening with human iPSCs;
- Human iPS cell generation, culture, differentiation and banking;
- In vitro disease modeling;
- Genetic engineering and molecular biology.
Contact: sacha.reichman@inserm.fr
Bio Sketch